| ¿µ¹® | plasma | ÇÑ±Û | Ç÷Àå |
|---|---|---|---|
| ¼³¸í | Ç÷¾×À̳ª ¸²ÇÁ¾×ÀÇ ¾×ü ºÎºÐÀ» ¸»Çϴµ¥, ÁÖ·Î Ç÷¾×¿¡¼ °íÇü¼ººÐ(Ç÷±¸¼¼Æ÷)À» Á¦¿ÜÇÑ ¾×ü ºÎºÐÀ» ÀǹÌÇÑ´Ù. ¿©±â¿¡´Â ´Ü¹é¼ººÐ(¸é¿ªÇö»óÀ» À¯¹ßÇÏ´Â Ç×ü¸¦ Æ÷ÇÔÇÔ), ¿µ¾ç¼ººÐ(°¢ ¼¼Æ÷¿¡ ¿µ¾çºÐÀ» °ø±ÞÇÔ), ±×¸®°í Ç÷¾×ÀÀ°í ¼ººÐ(»óó°¡ ³µÀ» ¶§ ÃâÇ÷ÀÌ ¸ÜÀ» ¼ö ÀÖµµ·Ï ÇÔ) µîÀÌ Æ÷ÇԵȴÙ. |
||
| ¿µ¹® | plasma membrane | ÇÑ±Û | ÇüÁú¸· |
|---|---|---|---|
| ¼³¸í | ¿øÇüÁú Ç¥¸éÀ» µ¤´Â ¿¯Àº¸·. µÎ²²´Â 5~25¥ìmÀÌ´Ù. ±¤ÇÐÇö¹Ì°æÀ¸·Î´Â °üÂûÇÒ ¼ö ¾øÁö¸¸ ÀüÀÚÇö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÏ´Ù. ¿øÇüÁú¸·ÀÇ ºÐÀÚ±¸Á¶´Â ·¹½ÃƾÀ̳ª ÄÝ·¹½ºÅ×·Ñ µîÀÇ Ç¥¸é Ȱ¼º¹°Áú ºÐÀÚ°¡ 2ºÐÀÚÃþÀ¸·Î ±× Ç¥¸é¿¡ ¹è¿µÇ¸ç, À̰ÍÀ» °¢ 1ºÐÀÚÃþÀÇ ´Ü¹éÁú ºÐÀÚ°¡ ¾çÂÊ¿¡¼ »÷µåÀ§Ä¡ÇÑ ´ÜÀ§¸· ±¸Á¶ÀÌ´Ù. ÀüÀÚÇö¹Ì°æÀûÀ¸·Î ÀÌ ´ÜÀ§´Â ¾Ï-¸í-¾ÏÀÇ 3Ãþ(°¢ ¾à 20nm)À¸·Î ±¸º°µÈ´Ù. ¿øÇüÁúÀÇ Åõ°ú¼º¿¡ Áß¿äÇÑ ±¸½ÇÀ» Çϸç, »ý¸®»óŰ¡ º¯ÇÏ¸é ±× Åõ°ú¼ºµµ ½Å¼ÓÈ÷ º¯ÇÑ´Ù. ¶Ç, ¼Õ»óÀÌ µÇ¸é ½±°Ô »õ·Î Çü¼ºµÈ´Ù. |
||
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
|---|---|
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| PTC | 1) Percutaneous Transhepatic Cholangiography = PTHC ... |
| PT | pain threshold; parathormone; parathyroid; paroxysmal tachycardia; part time; patient; pericardial t... |
| PTA | parallel tubular arrays; parathyroid adenoma; percutaneous transluminal angioplasty; peroxidase-labe... |
| APTT | Activated Partial Thromboplastin Time |
|---|---|
| APTT | Activated partial thromboplastin |
| aPTT | Partial thromboplastin time |
| TP | thromboplastin |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
| plasma thromboplastin antecedent | <chemical> Stable blood coagulation factor involved in the intrinsic pathway. The activated form xia activates factor ix to ixa. Deficiency of factor xi is often called haemophilia c. Chemical name: Blood-coagulation factor XI (12 Dec 1998) |
|---|---|
| plasma thromboplastin component | <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b). Chemical name: Blood-coagulation factor IX (12 Dec 1998) |
| plasma thromboplastin factor | A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs. (12 Dec 1998) |
| plasma thromboplastin factor B | <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b). Chemical name: Blood-coagulation factor IX (12 Dec 1998) |
| activated partial thromboplastin time | The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system. (05 Mar 2000) |
| partial thromboplastin time | Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy. (12 Dec 1998) |
| thromboplastin | <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin). (18 Nov 1997) |
| tissue thromboplastin inhibition time | A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors. (05 Mar 2000) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|